vs

Side-by-side financial comparison of CapsoVision, Inc (CV) and Token Cat Ltd (TC). Click either name above to swap in a different company.

CapsoVision, Inc is the larger business by last-quarter revenue ($3.5M vs $2.8M, roughly 1.3× Token Cat Ltd). Token Cat Ltd runs the higher net margin — -3.4% vs -223.9%, a 220.5% gap on every dollar of revenue.

CapsoVision, Inc. is a medical technology firm specializing in the development and manufacturing of advanced capsule endoscopy systems and supporting diagnostic solutions. Its non-invasive gastrointestinal imaging products are supplied to hospitals, gastroenterology clinics and medical specialists across global markets, supporting more accurate detection of digestive diseases and improved patient care experiences.

CV vs TC — Head-to-Head

Bigger by revenue
CV
CV
1.3× larger
CV
$3.5M
$2.8M
TC
Higher net margin
TC
TC
220.5% more per $
TC
-3.4%
-223.9%
CV

Income Statement — Q3 FY2025 vs Q2 FY2025

Metric
CV
CV
TC
TC
Revenue
$3.5M
$2.8M
Net Profit
$-7.9M
$-93.0K
Gross Margin
54.1%
79.0%
Operating Margin
-226.7%
-206.9%
Net Margin
-223.9%
-3.4%
Revenue YoY
-37.9%
Net Profit YoY
98.3%
EPS (diluted)
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CV
CV
TC
TC
Q3 25
$3.5M
Q2 25
$3.3M
$2.8M
Q2 24
$4.4M
Q2 23
$12.7M
Q2 22
$13.3M
Net Profit
CV
CV
TC
TC
Q3 25
$-7.9M
Q2 25
$-4.6M
$-93.0K
Q2 24
$-5.6M
Q2 23
$-4.2M
Q2 22
$-8.4M
Gross Margin
CV
CV
TC
TC
Q3 25
54.1%
Q2 25
54.6%
79.0%
Q2 24
69.2%
Q2 23
63.4%
Q2 22
81.0%
Operating Margin
CV
CV
TC
TC
Q3 25
-226.7%
Q2 25
-140.3%
-206.9%
Q2 24
-146.9%
Q2 23
-59.9%
Q2 22
-49.6%
Net Margin
CV
CV
TC
TC
Q3 25
-223.9%
Q2 25
-139.5%
-3.4%
Q2 24
-125.9%
Q2 23
-33.3%
Q2 22
-62.9%
EPS (diluted)
CV
CV
TC
TC
Q3 25
$-0.17
Q2 25
$-2.02
Q2 24
Q2 23
Q2 22
$-0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CV
CV
TC
TC
Cash + ST InvestmentsLiquidity on hand
$150.0K
Total DebtLower is stronger
$1.4M
Stockholders' EquityBook value
$20.4M
$4.6M
Total Assets
$25.7M
$28.4M
Debt / EquityLower = less leverage
0.30×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CV
CV
TC
TC
Q3 25
Q2 25
$150.0K
Q2 24
$689.0K
Q2 23
$3.0M
Q2 22
$4.8M
Total Debt
CV
CV
TC
TC
Q3 25
Q2 25
$1.4M
Q2 24
$1.8M
Q2 23
Q2 22
Stockholders' Equity
CV
CV
TC
TC
Q3 25
$20.4M
Q2 25
$-139.0M
$4.6M
Q2 24
$-787.0K
Q2 23
$9.1M
Q2 22
$21.4M
Total Assets
CV
CV
TC
TC
Q3 25
$25.7M
Q2 25
$9.5M
$28.4M
Q2 24
$12.5M
Q2 23
$25.1M
Q2 22
$40.6M
Debt / Equity
CV
CV
TC
TC
Q3 25
Q2 25
0.30×
Q2 24
Q2 23
Q2 22

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CV
CV
TC
TC
Operating Cash FlowLast quarter
$-5.7M
$-23.7M
Free Cash FlowOCF − Capex
$-5.7M
FCF MarginFCF / Revenue
-160.5%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CV
CV
TC
TC
Q3 25
$-5.7M
Q2 25
$-9.5M
$-23.7M
Q2 24
$-1.5M
Q2 23
$-7.2M
Q2 22
$-8.3M
Free Cash Flow
CV
CV
TC
TC
Q3 25
$-5.7M
Q2 25
$-9.6M
Q2 24
$-1.5M
Q2 23
Q2 22
$-8.3M
FCF Margin
CV
CV
TC
TC
Q3 25
-160.5%
Q2 25
-289.0%
Q2 24
-34.4%
Q2 23
Q2 22
-62.2%
Capex Intensity
CV
CV
TC
TC
Q3 25
0.3%
Q2 25
2.1%
Q2 24
0.0%
Q2 23
Q2 22
0.1%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CV
CV

Products$2.5M71%
Other$1.0M29%

TC
TC

Segment breakdown not available.

Related Comparisons